RE:RE:RE:RE:RE:Let's stay focused..
I don't think there is going to be a buyout very easily. This is RDW's legacy. Game change to oncology care (which I believe it can be). He wants to ride it to the top one day.
FDA approval is for sure in my mind. You don't get have many oncology drugs that can care the malignancy in a third of patients after 1 (maybe 2) treatments.
However, it could still be slow as TLT doesn't have the money for the top tier FDA consultants.